Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20919753 | 0.81 | CHRM2 (0.33) | ALDH1A1TRIM24TRIM33 | |
| SCHEMBL4475232 | 0.81 | CYP2A6 (0.33) | — | |
| SCHEMBL14047327 | 0.79 | — | — | |
| SCHEMBL2997559 | 0.75 | BRD4 (0.42) | ALDH1A1 | |
| SCHEMBL2929497 | 0.75 | CHRM2 (0.32) | — | |
| SCHEMBL1440029 | 0.75 | ALDH1A1 (0.37) | ALDH1A1TRIM24TRIM33 | |
| SCHEMBL31013515 | 0.74 | — | — | |
| SCHEMBL442676 | 0.72 | BRD4 (0.44) | ALDH1A1 | |
| SCHEMBL2927812 | 0.72 | CHRM2 (0.33) | — | |
| SCHEMBL10525669 | 0.72 | BRD4 (0.39) | ALDH1A1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875626-B2 | 3,3,3-trifluoropropane-1-sulfonic acid 4-[1-(2-chlorophenyl)-3-methyl-4-oxo-5-piperidin-1-yl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine-2-yl]phenyl ester; treatment of obesity, psychiatric and neurological disorders | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| EP-1937679-B1 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-20080312269-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080262026-A1 | Therapeutic Agents 684 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| WO-2008120000-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008096151-A1 | PHARMACEUTICAL COMPOSITIONS OF CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1937679-A2 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007039740-A2 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| US-7071207-B2 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1432708-B1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262026-A1 | Therapeutic Agents 684 | GPR119, NLN, PYGB | ALDH1A1 618/4885TRIM24 4663/4885TRIM33 4532/4885 |
| US-20080009513-A1 | Therapeutic agents | NLN, GPR119, FABP4 | ALDH1A1 403/4885TRIM24 4499/4885TRIM33 4616/4885 |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | GPR119, GIPR, PGC | ALDH1A1 3534/4885TRIM24 4341/4885TRIM33 4005/4885 |
| US-20080312269-A1 | Therapeutic Agents | NLN, GRIN2C, GPR119 | ALDH1A1 612/4885TRIM24 4547/4885TRIM33 4437/4885 |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | GPR119, GIPR, PGC | ALDH1A1 2626/4885TRIM24 4194/4885TRIM33 4353/4885 |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | CNR1, CNR2, GPR18 | ALDH1A1 4335/4885TRIM24 3645/4885TRIM33 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.